Clinical Outcomes of Drug-Eluting Bead Transarterial Chemoembolization Loaded with Raltitrexed for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma

<div>A 56-year-old female treated by CB for advanced primary HCC in the right lobe. (a) A bulky tumor staining shown in the right lobe. (b)-(c) The tumor-feeding artery was super-selectively catheterized and embolized by 300–500 <i>μ</i>m raltitrexed-loaded beads. (d)–(f) The stable tumor with no enhancement found to shrink at 1.6-, 3.6-, and 5.9-month follow-up.</div>

Canadian Journal of Gastroenterology and Hepatology

fig2

Figure 2

Figure 2: Clinical Outcomes of Drug-Eluting Bead Transarterial Chemoembolization Loaded with Raltitrexed for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma 

Figure 2 | Clinical Outcomes of Drug-Eluting Bead Transarterial Chemoembolization Loaded with Raltitrexed for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma 